---
document_datetime: 2025-07-25 17:48:48
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vildagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vildagliptin-metformin-hydrochloride-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.36424
conversion_datetime: 2025-12-22 17:14:40.732375
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Vildagliptin/Metformin hydrochloride Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 25/07/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                          | variations. B.II.b.1 Replacement or addition of a manufacturingsiteforpartor allofthe manufacturing process of the finished product - B.1I1.b.1.a Secondary packaging site - Accepted B.II.b.2.cReplacement or addition of a manufacturer responsible for importation and/or batch release - B.11.b.2.c.2 Including batchcontrol/testing-Accepted                      |            | PL          | EMA/VR/0000287822   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|---------------------|
| Variation type IA_IN / EMA/VR/0000261613 | C.I.3Change(s)in theSummary ofProduct Characteristics,LabellingorPackageLeaflet of human medicinalproducts intended to implementtheoutcomeofaprocedure concermingPSURorPASS,or the outcome of theassessmentdonebythecompetent authority under Articles 45 or 46 of Regulation 1901/2006 - C.1.3.a Implementation of wording agreed by the competent authority-Accepted | 03/04/2025 | SmPC and PL |                     |